for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evogene Ltd

EVGN.OQ

Latest Trade

6.08USD

Change

0.13(+2.18%)

Volume

566,965

Today's Range

6.04

 - 

6.94

52 Week Range

0.75

 - 

6.94

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.95
Open
6.04
Volume
566,965
3M AVG Volume
5.70
Today's High
6.94
Today's Low
6.04
52 Week High
6.94
52 Week Low
0.75
Shares Out (MIL)
36.49
Market Cap (MIL)
696.99
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Evogene Reports Third Quarter 2020 Financial Results

Lavie Bio Announces Positive Results For LAV311 And LAV312 In Its Bio-Fungicide Program

Biomica Initiates Large-Scale Production Of Live Bacterial Product Candidate Consortium

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evogene Ltd

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Industry

Biotechnology & Drugs

Contact Info

13 Gad Feinstein st.

Park Rehovot P.O.B 2100

7612002

Israel

+972.8.9311900

http://www.evogene.com/

Executive Leadership

Martin S. Gerstel

Chairman of the Board

Ofer Haviv

President, Chief Executive Officer

Alex Taskar

Chief Financial Officer

Ido Dor

Executive Vice President & General Manager Ag-Biologicals

Mark Kapel

Executive Vice President-Technology

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
272.06
Price To Book (MRQ)
3.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.48
LT Debt To Equity (MRQ)
3.72
Return on Investment (TTM)
-43.15
Return on Equity (TTM)
-33.89

Latest News

Latest News

BRIEF-Evogene And Marrone Bio Innovations Announce Phase Advancement In Their Insect Control Collaboration

* EVOGENE AND MARRONE BIO INNOVATIONS ANNOUNCE PHASE ADVANCEMENT IN THEIR INSECT CONTROL COLLABORATION

BRIEF-Evogene Reports Q4 Loss Per Share $0.24

* EVOGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Evogene Announces Positive 2nd Year Field Trial Results In Corn Bio-Stimulant Ag-Biologicals Program

* EVOGENE ANNOUNCES POSITIVE 2ND YEAR FIELD TRIAL RESULTS IN CORN BIO-STIMULANT AG-BIOLOGICALS PROGRAM Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up